Skip to Content

Join the 'Byetta' group to help and get support from people like you.

Byetta News

Too Many Seniors With Diabetes Are Overtreated, Study Suggests

Posted 29 Oct 2015 by

THURSDAY, Oct. 29, 2015 – When it comes to treating seniors with diabetes, new research suggests that doctors often don't cut back on medications, even when treatment goals are surpassed. The study found that when people had potentially dangerous low blood sugar levels, just 27 percent had their medicines decreased. And when blood pressure treatments lowered blood pressure levels too much, just 19 percent saw a reduction in their medications. "As people get older, the risks of overtreating become greater, and the benefits become shorter. We have to start emphasizing that more isn't always better," said study author Dr. Jeremy Sussman, an assistant professor of internal medicine at the University of Michigan in Ann Arbor and a primary care doctor at the Ann Arbor VA System. The findings were published online Oct. 26 in the journal JAMA Internal Medicine. Practice guidelines generally ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Glyburide, Actos, Lantus Solostar, Bydureon, Levemir, Invokana, Glimepiride, Novolin R

Health Tip: Diabetes Can Take a Toll on Teeth and Mouth

Posted 10 Aug 2015 by

-- Diabetes, especially when uncontrolled, can cause damage to your mouth and teeth. The website says possible effects of diabetes on the teeth and mouth include: Dry mouth, due to decreased saliva production. Increased risk of cavities due to less saliva. Gingivitis, characterized by bleeding, inflamed gums. Difficulty tasting food. Slower healing of mouth wounds. Increased risk of infection. Among diabetic children. teeth emerging earlier than expected. Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Oral and Dental Conditions, Xerostomia, Lantus, Januvia, Diabetes, Type 1, Glucophage, Novolog, Toothache, Glipizide, Humalog, Diabetic Neuropathy, Burning Mouth Syndrome, Janumet, Byetta, Glyburide, Diabetic Nerve Damage

People With Type 2 Diabetes Do Benefit From Blood Sugar Checks

Posted 5 Aug 2015 by

WEDNESDAY, Aug. 5, 2015 – Personalized blood sugar self-monitoring benefits people with type 2 diabetes even if they're not taking insulin, a new small study shows. Some experts have questioned the value of self-monitoring in this group, and many insurers – including Medicare – limit the reimbursement of blood sugar (glucose) testing strips to one a day for people with type 2 diabetes. This study included 11 people with type 2 diabetes who worked with the researchers to create personalized, structured self-monitoring blood glucose schedules. In most cases, self-monitoring twice a day was the most helpful in providing meaningful information about blood sugar levels. However, there was room for individualization based on a patient's type of lifestyle and needs. For example, a patient might check their blood sugar twice a day three days a week instead of once a day seven days a week, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Glyburide, Actos, Lantus Solostar, Bydureon, Levemir, Invokana, Pre-Diabetes, Glimepiride

Certain Diabetes Drugs May Aid Weight Loss by Curbing Cravings

Posted 9 Jun 2015 by

TUESDAY, June 9, 2015 – A class of drugs used to treat diabetes also appears to help patients lose weight by changing how the brain responds to food, a new study suggests. Researchers have been trying to learn how gut-hormone based medications called GLP-1 receptor agonists also help people with type 2 diabetes shed excess pounds. A Dutch team said the drugs may reduce cravings and increase satisfaction while eating. The researchers looked specifically at the injectable GLP-1 receptor agonist exenatide (Bydureon, Byetta). Their findings are to be presented Tuesday at the American Diabetes Association (ADA) annual meeting in Boston. Studies presented at meetings are generally viewed as preliminary until they've been published in a peer-reviewed journal. "When you eat, there are several hormones released. GLP-1 is one of them," Dr. Liselotte van Bloemendaal, a Ph.D. student at the ... Read more

Related support groups: Diabetes, Type 2, Obesity, Weight Loss, Byetta, Bydureon, Exenatide

Study Sees No Evidence Linking Diabetes Drugs With Pancreatic Cancer

Posted 26 Feb 2014 by

WEDNESDAY, Feb. 26, 2014 – There's no firm evidence that the type 2 diabetes medications known as incretin-based drugs cause pancreatitis or pancreatic cancer, U.S. and European health officials say. But it's too early to say there's definitely no link between the injectable drugs and pancreatitis or pancreatic cancer, according to the safety assessment by the U.S. Food and Drug Administration (FDA) and its counterpart overseas, the European Medicines Agency (EMA). "Both agencies agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data," states the report in the Feb. 27 issue of the New England Journal of Medicine. "The FDA and the EMA have not reached a final conclusion at this time regarding such a causal ... Read more

Related support groups: Victoza, Januvia, Byetta, Pancreatitis, Bydureon, Pancreatic Cancer, Onglyza, Liraglutide, Sitagliptin, Exenatide, Saxagliptin

FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas

Posted 14 Mar 2013 by

ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes. FDA has asked the researchers to provide the methodology used to collect and study these specimens and to provide the tissue samples so the Agency can further investigate potential pancreatic toxicity associated with the incretin mimetics. BACKGROUND: Drugs in the incretin mimetic class include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin ... Read more

Related support groups: Diabetes, Type 2, Victoza, Januvia, Janumet, Byetta, Bydureon, Tradjenta, Liraglutide, Sitagliptin, Jentadueto, Linagliptin, Exenatide, Metformin/Sitagliptin, Oseni, Alogliptin, Nesina, Alogliptin/pioglitazone, Kazano, Juvisync, Alogliptin/metformin

Certain Diabetes Medications May Lower Heart Failure Risk

Posted 10 Mar 2013 by

SUNDAY, March 10 – A newer class of diabetes drugs may offer an extra benefit: A new study suggests these medications lower the odds of suffering heart failure. Researchers from Henry Ford Hospital in Detroit found that patients taking so-called GLP-1 drugs – including brand-name medications such as Byetta, Januvia and Victoza – were more than 40 percent less likely to be hospitalized for heart failure than patients prescribed other blood sugar-lowering medications. GLP-1 diabetes drugs have been in use for only the last several years and are considered second-line treatments after well-established medications such as metformin, physicians said. "I don't think we can say this will magically prevent all heart failure deaths, but the strength of the association warrants more investigation," said study author and cardiologist Dr. David Lanfear. "Heart failure is a very common disease . ... Read more

Related support groups: Diabetes, Type 2, Victoza, Heart Failure, Congestive Heart Failure, Januvia, Byetta, Bydureon, Liraglutide, Sitagliptin, Exenatide

Newest Diabetes Drugs Linked to Higher Pancreatitis Risk

Posted 25 Feb 2013 by

MONDAY, Feb. 25 – Diabetes patients who take the latest class of drugs to control blood sugar levels are twice as likely to develop pancreatitis as those who take other medications to control blood sugar, according to a new study. The drugs Januvia (sitagliptin) and Byetta (exenatide) are glucagon-like peptide-1-based (GLP-1) therapies, which are used by millions of Americans with diabetes. Pancreatitis is inflammation of the pancreas, the organ that releases hormones such as insulin and glucagon, as well as enzymes that help digest food. Pancreatitis is a painful condition that can be dangerous if left untreated. People with diabetes are already at higher risk for pancreatitis because of the role the pancreas plays in the condition. In this study, researchers from Johns Hopkins University in Baltimore compared nearly 1,300 type 2 diabetes patients who took one of the GLP-1 drugs with ... Read more

Related support groups: Diabetes, Type 2, Januvia, Byetta, Pancreatitis, Bydureon, Sitagliptin, Exenatide

Diabetes Drug Byetta May Offer 'Modest' Weight Loss for Very Obese Teens: Study

Posted 5 Feb 2013 by

TUESDAY, Feb 5 – The drug Byetta, approved for adults with type 2 diabetes, appears to help severely obese teens lose some weight, a small study found. Researchers assigned 26 teens, ages 12 to 19, either to injections of Byetta (exenatide) or placebo injections twice daily. After three months, those who got the drug had a nearly 3 percent greater reduction in their body mass index (BMI, a measure of height versus weight) compared to those on placebo. However, that difference remains "modest," said researcher Aaron Kelly, assistant professor of pediatrics at the University of Minnesota Medical School and Amplatz Children's Hospital. "We are not proposing this be prescribed clinically," he said. The study was small, only lasted six months and more study is needed, he added. According to Kelly, Byetta may only be another tool to help the 4 percent to 6 percent of U.S. children and teens ... Read more

Related support groups: Diabetes, Type 2, Obesity, Byetta, Bydureon, Exenatide

New Diabetes Drugs Have Different Advantages, Study Says

Posted 7 Nov 2012 by

WEDNESDAY, Nov. 7 – A head-to-head comparison of two new type 2 diabetes drugs produced mixed results. In the study, liraglutide (Victoza) was somewhat better than the other drug, exenatide (Bydureon), in lowering blood sugar and weight, but Bydureon was associated with fewer side effects, researchers said. Victoza is injected daily by patients and Bydureon is injected weekly. Both drugs are classified as "glucagon-like peptide-1 receptor agonists." "These treatments are very powerful blood sugar-lowering agents that don't cause [too-low] blood sugar and are associated with weight loss," said lead researcher Dr. John Buse, a professor of medicine at the University of North Carolina at Chapel Hill. "That's a unique profile for a diabetes drug." Patients can choose between them, Buse said. A lot depends on what the person is comfortable with. "You lay this all out for patients and help ... Read more

Related support groups: Diabetes, Type 2, Victoza, Byetta, Bydureon, Liraglutide, Exenatide

Prescription Meds Can Put on Unwanted Pounds

Posted 2 Mar 2012 by

FRIDAY, March 2 – Medications taken by millions of Americans for mood disorders, high blood pressure, diabetes and other chronic conditions can have an unhealthy side effect: weight gain. While other choices exist for some types of drugs, adjusting medications is not simply a matter of switching, said Ryan Roux, chief pharmacy officer with the Harris County Hospital District, in Houston. In the late 1990s, Dr. Lawrence Cheskin conducted early research on prescription medicines and obesity. "Some medicines make an early, noticeable difference, causing patients to become ravenously hungry, while changes are subtle for others. A few months taking them and you've gained 10 pounds," said Cheskin, now director of the Johns Hopkins Weight Management Center, in Baltimore. To help increase awareness, Roux and his pharmacist group have compiled a list of "weight-promoting" and "weight-neutral or ... Read more

Related support groups: Bipolar Disorder, High Blood Pressure, Plan B, Diabetes, Type 2, Zoloft, Wellbutrin, Prednisone, Prozac, Gabapentin, Mirena, Metformin, Sprintec, NuvaRing, Seroquel, Hypertension, Implanon, Provera, Paxil, Metoprolol, Nexplanon

Certain Diabetes Drugs Might Aid Weight Loss

Posted 11 Jan 2012 by

TUESDAY, Jan. 10 – A class of newer diabetes drugs that includes exenatide (Byetta, Bydureon) might also be used to help the obese lose weight, Danish researchers report. That's because weight loss and lowered cholesterol are often side effects of these drugs, called "glucagon-like peptide-1 receptor agonists" (GLP-1), the team noted. "If you use this treatment for 20 weeks, you have a positive effect on body weight," said lead researcher Dr. Tina Vilsboll, head of the Diabetes Research Division at Gentofte Hospital of the University of Copenhagen. "The hope is that we have a new class of treatment for obesity, and not just for type 2 diabetes." "It's not a wonder drug," Vilsboll stressed. "It doesn't make everyone normal weight, but it's a way of changing your lifestyle." And she does not recommend using these drugs as a standalone treatment for weight loss. "Not right now, we need ... Read more

Related support groups: Obesity, Byetta, Exenatide

Byetta Approved for Use with Insulin Glargine in the U.S.

Posted 30 Oct 2011 by

SAN DIEGO and INDIANAPOLIS, Oct. 19, 2011 /PRNewswire/ – Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has approved a new use for Byetta (exenatide) injection. Byetta is now approved as an add-on therapy to insulin glargine, with or without metformin and/or a thiazolidinedione (TZD), in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control on insulin glargine alone. "This expanded use for Byetta is important for clinical care, in that it provides a new option for the many patients with type 2 diabetes who are not achieving treatment goals," said John Buse, M.D., Ph.D., professor of medicine, director of the Diabetes Care Center and chief of the Division of Endocrinology at the University of North Carolina School of Medicine in Chapel Hill. "Byetta is ... Read more

Related support groups: Byetta

Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests

Posted 22 Sep 2011 by

THURSDAY, Sept. 22 – People with type 2 diabetes taking the drugs Januvia or Byetta might have an increased risk of developing pancreatitis and pancreatic cancer, a preliminary study suggests. The study also found that Byetta (exenatide) may raise the risk of thyroid cancer. Although the links aren't conclusive, they merit further investigation, the researchers noted. "We have raised concern that there may be a link, but we haven't confirmed it," said lead researcher Dr. Peter Butler, director of the Larry L. Hillblom Islet Research Center at the University of California, Los Angeles. "We need to do more work to figure out whether this is real or not." Both drugs help control blood sugar levels by encouraging production of a hormone called glucagon-like peptide 1 (GLP-1). Januvia (sitagliptin) and Byetta, an injectable drug, are a new way of treating type 2 diabetes, and they ... Read more

Related support groups: Diabetes, Type 2, Januvia, Byetta, Pancreatitis, Pancreatic Cancer

FDA Asks for Risk Plan Info on Diabetes Drug

Posted 15 Mar 2010 by

From Associated Press (March 15, 2010) SAN DIEGO – Amylin Pharmaceuticals Inc. said Monday it received a Food and Drug Administration request for information on manufacturing and a risk mitigation plan for a potential once-weekly diabetes treatment. Amylin, along with partners Eli Lilly & Co. and Alkermes Inc., are not being asked to conduct additional studies on the much anticipated drug. The FDA request focuses on product labeling for Bydureon, which is the proposed trade name for exenatide, along with risk mitigation and manufacturing information. The FDA response does not contain requests related to a December preapproval inspection of a manufacturing facility in Ohio. Amylin said it is "working diligently" to submit a response to the FDA in the next few weeks. Bydureon, or exenatide, is a once-weekly version of the injectable treatment Byetta, which is currently taken twice daily. ... Read more

Related support groups: Byetta, Exenatide

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Byetta Patient Information at